Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AGO Study Group
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Relapse longer than 6 months after termination of platinum/taxane based first line chemotherapy
Previously histologically confirmed cancer of: ovary, fallopian tube, peritoneum
measurable and evaluable lesions by ultrasound, computer-tomography or MRI
Performance status ECOG \< 2 or karnofsky index \> 60%
normal organ function
You may not be if
more than 1 chemotherapy prior enrollment
ongoing treatment with epoetin alpha or related drugs
history of thrombosis or embolism during the past 12 months prior enrollment
ileus
left ventricular failure \> NYHA classification \> 2
Ongoing toxicity of any kind (\> CTC Grad II)
Clareo Health | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
